Loading data for CNTX — first visit, this takes a few seconds.
Context Therapeutics Inc. (CNTX)
NasdaqCM: CNTX
· Real-Time Price · USD
0.41
-0.01 (-2.38%)
At close: Aug 28, 2026, 8:00 PM
0.40
+3.67%
After-hours: 7:45 PM
The price, the headline numbers and the latest news, in one place.
Context Therapeutics Inc. (CNTX) Stock Price, Analysis & Data
-2.38% (1D)
No data available
| Bid | 0.29 |
| Market Cap | 35.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.96M |
| 1.75 | |
| -0.44 | |
| n/a | |
| -0.88 | |
| P/B (ttm) | 0.92 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 0.55 |
| Volume | 272,691 |
| Avg. Volume (20D) | 2,807,800 |
| Open | 0.41 |
| Previous Close | 0.42 |
| Day's Range | 0.40 - 0.42 |
| 52-Week Range | 0.40 - 3.62 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2021
Employees 15
Stock Exchange NasdaqCM
Ticker Symbol CNTX
Financial Performance
In 2025, Context Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -36.12M, an increase of 35.17%.
Financial StatementsEarnings Surprise
Context Therapeutics has released their quarterly earnings on Aug 5, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.15 misses estimates by -0.06, with -66.67% YoY decline.